EMEA-002533-PIP01-18

Key facts

Active substance
  • salbutamol sulfate
  • budesonide
Therapeutic area
Pneumology-allergology
Decision number
P/0185/2019
PIP number
EMEA-002533-PIP01-18
Pharmaceutical form(s)
Pressurised inhalation, suspension
Condition(s) / indication(s)
Treatment of asthma
Route(s) of administration
Inhalation use
Contact for public enquiries
AstraZeneca AB (UK)

Tel. +44 2037496236
E-mail: paediatrics@astrazeneca.com

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating